New insights into the pharmacokinetics of spironolactone
Four healthy men took a single oral dose of 200 mg spironolactone after a standardized breakfast. Blood samples were drawn until 24 hours after dosing. A specific HPLC method was used to determine the serum concentrations of spironolactone and its metabolites 7 alpha-thiomethylspirolactone, 6 beta-h...
Saved in:
Published in | Clinical pharmacology and therapeutics Vol. 38; no. 4; p. 469 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
01.10.1985
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Four healthy men took a single oral dose of 200 mg spironolactone after a standardized breakfast. Blood samples were drawn until 24 hours after dosing. A specific HPLC method was used to determine the serum concentrations of spironolactone and its metabolites 7 alpha-thiomethylspirolactone, 6 beta-hydroxy-7 alpha-thiomethylspirolactone, and canrenone. Pharmacokinetic parameters were derived from the serum concentration-time course of each compound. Spironolactone, 7 alpha-thiomethylspirolactone, and canrenone are known to have antimineralocorticoid activity in man. Our study demonstrated that: (1) 7 alpha-Thiomethylspirolactone is the main metabolite of spironolactone after a single oral dose as judged by the AUC(0-24) and the maximum concentration; and (2) unchanged spironolactone was detected in serum, with a maximum concentration at 1 hour and detectable levels up to 8 hours after dosing. Our findings are contrary to the widely accepted belief that spironolactone is metabolized too rapidly to be detected in serum after oral dosing and that canrenone is the principal metabolite of spironolactone. |
---|---|
AbstractList | Four healthy men took a single oral dose of 200 mg spironolactone after a standardized breakfast. Blood samples were drawn until 24 hours after dosing. A specific HPLC method was used to determine the serum concentrations of spironolactone and its metabolites 7 alpha-thiomethylspirolactone, 6 beta-hydroxy-7 alpha-thiomethylspirolactone, and canrenone. Pharmacokinetic parameters were derived from the serum concentration-time course of each compound. Spironolactone, 7 alpha-thiomethylspirolactone, and canrenone are known to have antimineralocorticoid activity in man. Our study demonstrated that: (1) 7 alpha-Thiomethylspirolactone is the main metabolite of spironolactone after a single oral dose as judged by the AUC(0-24) and the maximum concentration; and (2) unchanged spironolactone was detected in serum, with a maximum concentration at 1 hour and detectable levels up to 8 hours after dosing. Our findings are contrary to the widely accepted belief that spironolactone is metabolized too rapidly to be detected in serum after oral dosing and that canrenone is the principal metabolite of spironolactone. |
Author | Hermens, W A Overdiek, H W Merkus, F W |
Author_xml | – sequence: 1 givenname: H W surname: Overdiek fullname: Overdiek, H W – sequence: 2 givenname: W A surname: Hermens fullname: Hermens, W A – sequence: 3 givenname: F W surname: Merkus fullname: Merkus, F W |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/4042530$$D View this record in MEDLINE/PubMed |
BookMark | eNotj7FOwzAURT0UlbYwMiLlBxKe7dh5HlEFFKmCBebKcV6IIYmj2Ajx90Si071nuUd3y1ZjGImxGw4FB4l3rp9SwQ2qQoBesQ0AmNwIqS_ZNsbPBUuDuGbrEkqhJGwYvtBP5sfoP7oUl5JCljrKps7Og3Xhy4-UvItZaLM4-TmMobcuLdYrdtHaPtL1OXfs_fHhbX_Ij69Pz_v7Y-6kkTpvOEmpSFoyvCIyWgleI4EEXTVSNEiIJHhbWY0VkqsU1hodOCekEsqKHbv9352-64Ga0zT7wc6_p_MD8Qc0MEek |
CitedBy_id | crossref_primary_10_1016_0378_4347_87_80044_0 crossref_primary_10_1002_jms_166 crossref_primary_10_1080_08037051_2022_2061416 crossref_primary_10_1016_0006_2952_88_90741_1 crossref_primary_10_1016_0021_9673_93_83228_K crossref_primary_10_1002_hep_1840130531 crossref_primary_10_1016_S1084_2756_98_80033_X crossref_primary_10_1007_s11789_006_0025_x crossref_primary_10_1016_S0002_9629_15_40677_9 crossref_primary_10_1007_s00228_023_03599_w crossref_primary_10_1517_13543784_2015_1059819 crossref_primary_10_1124_jpet_117_241703 crossref_primary_10_1111_nmo_14084 crossref_primary_10_1016_S0167_5273_02_00193_6 crossref_primary_10_1080_01961779308048955 crossref_primary_10_1371_journal_pone_0100829 crossref_primary_10_1097_00000441_200001000_00003 crossref_primary_10_3892_mmr_2019_10039 crossref_primary_10_1097_00000441_200001000_00004 crossref_primary_10_1007_BF00315231 crossref_primary_10_1016_j_jchromb_2006_02_017 crossref_primary_10_1016_S0021_9673_97_01167_9 crossref_primary_10_1111_j_1365_4362_1996_tb02970_x crossref_primary_10_1515_DMDI_1988_6_3_4_337 crossref_primary_10_1111_j_2042_7158_1998_tb06894_x crossref_primary_10_1002_med_2610110604 crossref_primary_10_1007_BF00314854 crossref_primary_10_1007_BF00316635 crossref_primary_10_1016_S0002_9629_15_40678_0 crossref_primary_10_1016_0378_4347_94_00241_X crossref_primary_10_1002_ibd_21929 crossref_primary_10_1111_j_1600_0765_2005_00792_x crossref_primary_10_1080_13543784_2021_2002844 crossref_primary_10_1002_bmc_4287 crossref_primary_10_1002_j_1552_4604_1989_tb03339_x crossref_primary_10_1016_0006_2952_87_90323_6 crossref_primary_10_2165_00148581_200608040_00004 crossref_primary_10_1124_dmd_110_032870 crossref_primary_10_1016_0016_5085_92_91730_R crossref_primary_10_1016_S0031_3955_16_36880_8 crossref_primary_10_1016_0378_4347_92_80097_A crossref_primary_10_1016_j_pharmthera_2015_07_006 crossref_primary_10_1093_eurheartj_ehr170 crossref_primary_10_1136_gutjnl_2020_321790 crossref_primary_10_1056_NEJM199808063390607 crossref_primary_10_1038_sj_bjp_0706700 crossref_primary_10_1038_hr_2012_182 crossref_primary_10_1185_03007999109111516 crossref_primary_10_1046_j_1523_1755_2000_00055_x crossref_primary_10_1016_0022_3956_93_90038_4 crossref_primary_10_1097_FJC_0000000000001316 crossref_primary_10_1016_S0378_5173_97_00280_9 crossref_primary_10_1002_ejhf_1802 crossref_primary_10_1016_S0731_7085_96_01767_0 crossref_primary_10_1016_S0140_6736_85_92603_0 crossref_primary_10_1515_DMDI_1987_5_4_273 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1038/clpt.1985.206 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 4042530 |
Genre | Journal Article |
GroupedDBID | --- --K -Q- .55 .GJ 0R~ 1B1 1CY 1OB 1OC 29B 33P 354 36B 39C 3O- 4.4 52O 53G 5GY 5RE 6J9 70F 8F7 AAESR AAHHS AAKAS AANLZ AAONW AAQOH AAQQT AAWTL AAYOK AAZKR ABCUV ABJNI ABLJU ABQWH ACBNA ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACPOU ACXQS ADBBV ADBTR ADKYN ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AENEX AEQDE AEUYR AFBPY AFFNX AFFPM AHBTC AI. AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI C45 CAG CGR COF CS3 CUY CVF DCZOG DPXWK DU5 EBS ECM EE. EIF EJD EMOBN F5P GODZA HGLYW IH2 IHE J5H L7B LATKE LEEKS LITHE LOXES LSO LUTES LYRES M41 MEWTI N4W N9A NPM NQ- O9- OPC OVD P2P P2W PALCI RIG RIWAO RJQFR RNTTT ROL RPZ SAMSI SEW SJN SUPJJ TEORI TWZ UHS VH1 WBKPD WH7 WOHZO WXSBR WYJ X7M Y6R YCJ YFH YOC YXB ZGI ZXP ZZTAW |
ID | FETCH-LOGICAL-c3936-d1e335e3ae917ee96521b8e03067d32d8e88e21f7a6878ec758b68c0cc23525a2 |
ISSN | 0009-9236 |
IngestDate | Sat Sep 28 08:38:53 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3936-d1e335e3ae917ee96521b8e03067d32d8e88e21f7a6878ec758b68c0cc23525a2 |
PMID | 4042530 |
ParticipantIDs | pubmed_primary_4042530 |
PublicationCentury | 1900 |
PublicationDate | October 1985 |
PublicationDateYYYYMMDD | 1985-10-01 |
PublicationDate_xml | – month: 10 year: 1985 text: October 1985 |
PublicationDecade | 1980 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical pharmacology and therapeutics |
PublicationTitleAlternate | Clin Pharmacol Ther |
PublicationYear | 1985 |
SSID | ssj0004988 |
Score | 1.5128143 |
Snippet | Four healthy men took a single oral dose of 200 mg spironolactone after a standardized breakfast. Blood samples were drawn until 24 hours after dosing. A... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 469 |
SubjectTerms | Absorption Administration, Oral Adult Biotransformation Canrenone - blood Half-Life Humans Kinetics Male Spironolactone - analogs & derivatives Spironolactone - blood Spironolactone - metabolism |
Title | New insights into the pharmacokinetics of spironolactone |
URI | https://www.ncbi.nlm.nih.gov/pubmed/4042530 |
Volume | 38 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT8IwFG5EY8KL8Ua8pw-GFxnC2m3doyESYiLyAJE3srVdQtCxKD7gr_d07S7gJerLQtqljH6H0-_res5B6JI7URsMQVhhBBKFRi1qBQ4D1Rq6EawHApZ4FTt833d7I3o3dsZF_c40umQRNvn7l3El_0EV2gBXFSX7B2TzQaEBPgO-cAWE4forjNXhxGn8qvS1OlZlaGRislHPgECmSZiBD6r36fMYZCxXybfLjLSThUYmRRLrZXauMgvNyon3A8yRmMrUhfau8v2ZHvh3qRn5Y7E7ei9fZm9pY9fcKnS8HXPyg2qFy_QtYIFu2WUSVjINWvJ_VNdd-eSXdRZ2_pQsmupLQJe75ftgWpPnFCSqnIh-U_Nj51qSbNNTQRWPKT_XV3s2WXSsz1hWT0_9EJNpFR7peuWBqmjbDLMmMVKqMdxFO0Yj4BsN-B7akPE-qg80PssGHpaAaeA6HpSQO0CquBLOrAIrq8CAJF63CjyP8KpVHKJR93bY6VmmPobFiU9cS7QlIY4kgQTNLaXvAhULmUxVoCC2YJIxabcjL3CZxyQHaRi6jLc4t1US3MCuoc0Yhj9C2G4H1BMSlhxJaaCyV4eERiQEsg8EWXjHqKZnZJLoJCgTM1Un33WcomphTmdoK4L_nDwHArcIL1J8PgAV1URd |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+insights+into+the+pharmacokinetics+of+spironolactone&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Overdiek%2C+H+W&rft.au=Hermens%2C+W+A&rft.au=Merkus%2C+F+W&rft.date=1985-10-01&rft.issn=0009-9236&rft.volume=38&rft.issue=4&rft.spage=469&rft_id=info:doi/10.1038%2Fclpt.1985.206&rft_id=info%3Apmid%2F4042530&rft_id=info%3Apmid%2F4042530&rft.externalDocID=4042530 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9236&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9236&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9236&client=summon |